Molecular regulation of androgen action in prostate cancer

Journal of Cellular Biochemistry

Volumn 99, Issue 2, 2006, Pages 333-344

  Dehm, Scott M ^a   Tindall, Donald J ^a,b  

^a Mayo Clinic   (United States)

^b Department of Urologic Research ^*  (United States)

Author keywords

Androgen receptor; Gene expression; Prostate cancer; Transcription

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; CELL NUCLEUS RECEPTOR; TRANSCRIPTION FACTOR;

CANCER GROWTH; CANCER HORMONE THERAPY; CANCER SURVIVAL; CARCINOGENESIS; DISSEMINATED CANCER; GENE CONTROL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENETIC ANALYSIS; GENETIC REGULATION; HORMONAL REGULATION; HORMONE ACTION; HORMONE RECEPTOR INTERACTION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REGULATORY MECHANISM; REVIEW; SYSTEMIC THERAPY; TRANSCRIPTION REGULATION;

ADULT; ANDROGENS; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION PROFILING; HUMANS; MALE; MODELS, BIOLOGICAL; NEOPLASMS, HORMONE-DEPENDENT; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 33746623315     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.20794     Document Type: Review

References (61)

1. Afar DE, Vivanco I, Hubert RS, Kuo J, Chen E, Saffran DC, Raitano AB, Jakobovits A. 2001. Catalytic cleavage of the androgen-regulated TMPRSS2 protease results in its secretion by prostate and prostate cancer epithelia. Cancer Res 61:1686-1692.
2. Amler LC, Agus DB, LeDuc C, Sapinoso ML, Fox WD, Kern S, Lee D, Wang V, Leysens M, Higgins B, Martin J, Gerald W, Dracopoli N, Cordon-Cardo C, Scher HI, Hampton GM. 2000. Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1. Cancer Res 60:6134-6141.
3. Asirvatham AJ, Schmidt M, Gao B, Chaudhary J. 2005. Androgens regulate the immune/inflammatory response and cell survival pathways in rat ventral prostate epithelial cells. Endocrinology.
4. Brigstock DR. 2003. The CCN family: A new stimulus package. J Endocrinol 178:169-175.
5. Buchanan G, Irvine RA, Coetzee GA, Tilley WD. 2001. Contribution of the androgen receptor to prostate cancer predisposition and progression. Cancer Metastasis Rev 20:207-223.
6. Castoria G, Lombardi M, Barone MV, Bilancio A, Di Domenico M, Bottero D, Vitale F, Migliaccio A, Auricchio F. 2003. Androgen-stimulated DNA synthesis and cytoskeletal changes in fibroblasts by a nontranscriptional receptor action. J Cell Biol 161:547-556.
7. Che M, Grignon D. 2002. Pathology of prostate cancer. Cancer Metastasis Rev 21:381-395.
8. Claverie JM. 2005. Fewer genes, more noncoding RNA. Science 309:1529-1530.
9. Clegg N, Eroglu B, Ferguson C, Arnold H, Moorman A, Nelson PS. 2002. Digital expression profiles of the prostate androgen-response program. J Steroid Biochem Mol Biol 80:13-23.
10. de Launoit Y, Veilleux R, Dufour M, Simard J, Labrie F. 1991. Characteristics of the biphasic action of androgens and of the potent antiproliferative effects of the new pure antiestrogen EM-139 on cell cycle kinetic parameters in LNCaP human prostatic cancer cells. Cancer Res 51: 5165-5170.
11. DePrimo SE, Diehn M, Nelson JB, Reiter RE, Matese J, Fero M, Tibshirani R, Brown PO, Brooks JD. 2002. Transcriptional programs activated by exposure of human prostate cancer cells to androgen. Genome Biol 3: RESEARCH0032.
12. Desai KV, Michalowska AM, Kondaiah P, Ward JM, Shih JH, Green JE. 2004. Gene expression profiling identifies a unique androgen-mediated inflammatory/immune signature and a PTEN (phosphatase and tensin homolog deleted on chromosome 10)-mediated apoptotic response specific to the rat ventral prostate. Mol Endocrinol 18:2895-2907.
13. Eder IE, Culig Z, Ramoner R, Thurnher M, Putz T, Nessler-Menardi C, Tiefenthaler M, Bartsch G, Klocker H. 2000. Inhibition of LncaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. Cancer Gene Ther 7:997-1007.
14. Eder IE, Haag P, Basik M, Mousses S, Bektic J, Bartsch G, Klocker H. 2003. Gene expression changes following androgen receptor elimination in LNCaP prostate cancer cells. Mol Carcinog 37:181-191.
15. Febbo PG, Lowenberg M, Thorner AR, Brown M, Loda M, Golub TR. 2005. Androgen mediated regulation and functional implications of fkbpS 1 expression in prostate cancer. J Urol 173:1772-1777.
16. Feldman BJ, Feldman D. 2001. The development of androgen-independent prostate cancer. Nature Rev Cancer 1:34-45.
17. Gao S, Lee P, Wang H, Gerald W, Adler M, Zhang L, Wang/SNM〉 YF, Wang Z. 2005. The androgen receptor directly targets the c-FLIP gene to promote the androgen-independent growth of prostate cancer cells. Mol Endocrinol 24:24.
18. Grossmann ME, Huang H, Tindall DJ. 2001. Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 93:1687-1697.
19. Haag P, Bektic J, Bartsch G, Klocker H, Eder IE. 2005. Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells. J Steroid Biochem Mol Biol 24:24.
20. Heemers H, Verrijdt G, Organe S, Ciaessens F, Heyns W, Verhoeven G, Swinnen JV. 2004. Identification of an androgen response element in intron 8 of the sterol regulatory element-binding protein cleavage-activating protein gene allowing direct regulation by the androgen receptor. J Biol Chem 279:30880-30887.
21. Heinlein CA, Chang C. 2004. Androgen receptor in prostate cancer. Endocr Rev 25:276-308.
22. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ. 2004. Cancer statistics, 2004. CA Cancer J Clin 54:8-29.
23. Jiang F, Wang Z. 2003. Identification of androgen-responsive genes in the rat ventral prostate by complementary deoxyribonucleic acid subtraction and microarray. Endocrinology 144:1257-1165.
24. Kaaks R, Lukanova A, Sommersberg B. 2000. Plasma androgens, IGF-1, body size, and prostate cancer risk: A synthetic review. Prostate Cancer Prostatic Dis 3:157-172.
25. Kousteni S, Bellido T, Plotkin LI, O'Brien CA, Bodenner DL, Han L, Han K, DiGregorio GB, Katzenellenbogen JA, Katzenellenbogen BS, Roberson PK, Weinstein RS, Jilka RL, Manolagas SC. 2001. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: Dissociation from transcriptional activity. Cell 104:719-730.
26. Kurita T, Wang YZ, Donjacour AA, Zhao C, Lydon JP, O'Malley BW, Isaacs JT, Dahiya R, Cunha GR. 2001. Paracrine regulation of apoptosis by steroid hormones in the male and female reproductive system. Cell Death Differ 8:192-200.
27. Labrie F, Luu-The V, Labrie C, Simard J. 2001. DHEA and its transformation into androgens and estrogens in peripheral target tissues: Intracrinology. Front Neuroendocrinol 22:185-212.
28. Lamb DJ, Weigel NL, Marcelli M. 2001. Androgen receptors and their biology. Vitam Horm 62:199-230.
29. Liao X, Tang S, Thrasher JB, Griebling TL, Li B. 2005. Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer. Mol Cancer Ther 4:505-515.
30. Lilja H. 2003. Biology of prostate-specific antigen. Urology 62:27-33.
31. Lin B, Ferguson C, White JT, Wang S, Vessella R, True LD, Hood L, Nelson PS. 1999. Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res 59:4180-4184.
32. Lin B, White JT, Lu W, Xie T, Utleg AG, Yan X, Yi EC, Shannon P, Khrebtukova I, Lange PH, Goodlett DR, Zhou D, Vasicek TJ, Hood L. 2005. Evidence for the presence of disease-perturbed networks in prostate cancer cells by genomic and proteomic analyses: A systems approach to disease. Cancer Res 65:3081-3091.
33. Litvinov IV, De Marzo AM, Isaacs JT. 2003. Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab 88:2972-2982.
34. Meehan KL, Sadar MD. 2004. Quantitative profiling of LNCaP prostate cancer cells using isotope-coded affinity tags and mass spectrometry. Proteomics 4:1116-1134.
35. Migliaccio A, Castoria G, Di Domenico M, de Falco A, Bilancio A, Lombardi M, Barone MV, Ametrano D, Zannini MS, Abbondanza C, Auricchio F. 2000. Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. EMBO J 19:5406-5417.
36. Nantermet PV, Xu J, Yu Y, Hodor P, Holder D, Adamski S, Gentile MA, Kimmel DB, Harada S, Gerhold D, Freedman LP, Ray WJ. 2004. Identification of genetic pathways activated by the androgen receptor during the induction of proliferation in the ventral prostate gland. J Biol Chem 279:1310-1322.
37. Navarro D, Luzardo OP, Fernandez L, Chesa N, Diaz-Chico BN. 2002. Transition to androgen-independence in prostate cancer. J Steroid Biochem Mol Biol 81:191-201.
38. Nelson PS, Ng WL, Schummer M, True LD, Liu AY, Bumgarner RE, Ferguson C, Dimak A, Hood L. 1998. An expressed-sequence-tag database of the human prostate: Sequence analysis of 1168 cDNA clones. Genomics 47: 12-25.
39. Nelson PS, Clegg N, Arnold H, Ferguson C, Bonham M, White J, Hood L, Lin B. 2002. The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci USA 99:11890-11895.
40. Oosterhoff JK, Grootegoed JA, Blok LJ. 2005. Expression profiling of androgen-dependent and -independent LNCaP cells: EGF versus androgen signalling. Endocr Relat Cancer 12:135-148.
41. Oudes AJ, Roach JC, Walashek LS, Eichner LJ, True LD, Vessella RL, Liu AY. 2005. Application of Affymetrix array and Massively Parallel Signature Sequencing for identification of genes involved in prostate cancer progression. BMC Cancer 5:86.
42. Pandini G, Mineo R, Frasca F, Roberts CT, Jr, Marcelli M, Vigneri R, Belfiore A. 2005. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. Cancer Res 65:1849-1857.
43. Pfundt R, Smit F, Jansen C, Aalders T, Straatman H, van der Vliet W, Isaacs J, van Kessel AG, Schalken J. 2005. Identification of androgen-responsive genes that are alternatively regulated in androgen-dependent and androgen-independent rat prostate tumors. Genes Chromosomes Cancer 43:273-283.
44. Rokhlin OW, Taghiyev AF, Guseva NV, Glover RA, Chumakov PM, Kravchenko JE, Cohen MB. 2005. Androgen regulates apoptosis induced by TNFR family ligands via multiple signaling pathways in LNCaP. Oncogene 24:6773-6784.
45. Ronquist G, Nilsson BO. 2004. The Janus-faced nature of prostasomes: Their pluripotency favours the normal reproductive process and malignant prostate growth. Prostate Cancer Prostatic Dis 7:21-31.
46. Roth SY, Denu JM, Allis CD. 2001. Histone acetyltransferases. Annu Rev Biochem 70:81-120.
47. Roy-Burman P, Tindall DJ, Robins DM, Greenberg NM, Hendrix JC, Mohla S, Getzenberg RH, Isaacs JT, Pienta KJ. 2005. Androgens and prostate cancer: Are the descriptors valid? Cancer Biol Ther 4:4-5.
48. Segawa T, Nau ME, Xu LL, Chilukuri RN, Makarem M, Zhang W, Petrovics G, Sesterhenn IA, McLeod DG, Moul JW, Vahey M, Srivastava S. 2002. Androgen-induced expression of endoplasmic reticulum (ER) stress response genes in prostate cancer cells. Oncogene 21:8749-8758.
49. Shi XB, Ma AH, Tepper CG, Xia L, Gregg JP, Gandour-Edwards R, Mack PC, Rung HJ, deVere White RW. 2004. Molecular alterations associated with LNCaP cell progression to androgen independence. Prostate 60:257-271.
50. Steers WD. 2001. Salpha-reductase activity in the prostate. Urology 58:17-24; discussion 24.
51. Sung SY, Chung LW. 2002. Prostate tumor-stroma interaction: Molecular mechanisms and opportunities for therapeutic targeting. Differentiation 70:506-521.
52. Swinnen JV, Heemers H, van de Sande T, de Schrijver E, Brusselmans K, Heyns W, Verhoeven G. 2004. Androgens, lipogenesis and prostate cancer. J Steroid Biochem Mol Biol 92:273-279.
53. Thome M, Tschopp J. 2001. Regulation of lymphocyte proliferation and death by FLIP. Nat Rev Immunol 1:50-58.
54. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM. 2005. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310:644-648.
55. Vaarala MH, Porvari KS, Kellokumpu S, Kyllonen AP, Vihko PT. 2001. Expression of transmembrane serine protease TMPRSS2 in mouse and human tissues. J Pathol 193:134-140.
56. Velasco AM, Gillis KA, Li Y, Brown EL, Sadler TM, Achilleos M, Greenberger LM, Frost P, Bai W, Zhang Y. 2004. Identification and validation of novel androgen-regulated genes in prostate cancer. Endocrinology 145:3913-3924. Epub 2004 May 6.
57. Waghray A, Feroze F, Schober MS, Yao F, Wood C, Puravs E, Krause M, Hanash S, Chen YQ. 2001. Identification of androgen-regulated genes in the prostate cancer cell line LNCaP by serial analysis of gene expression and proteomic analysis. Proteomics 1:1327-1338.
58. Xu LL, Su YP, Labiche R, Segawa T, Shanmugam N, McLeod DG, Moul JW, Srivastava S. 2001. Quantitative expression profile of androgen-regulated genes in prostate cancer cells and identification of prostate-specific genes. Int J Cancer 92:322-328.
59. Ye D, Mendelsohn J, Fan Z. 1999. Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27Kip1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells. Clin Cancer Res 5:2171-2177.
60. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ. 2002. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 62:1008-1013.
61. Zhivotovsky B, Orrenius S. 2005. Caspase-2 function in response to DNA damage. Biochem Biophys Res Commun 331:859-867.